Active	Status	Sponsor type	Region	Phase	Filter
10 Active 14 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McIntyre, Roger
SMART-BD, NCT06433635: Sequential Multiple Assignment Randomized Trial for Bipolar Depression	Not yet recruiting	4	2726	Canada, US	Cariprazine, Vraylar, Aripiprazole/Escitalopram combination, Abilify/ Lexapro, Quetiapine, Seroquel, Lurasidone, Latuda	Massachusetts General Hospital, Patient-Centered Outcomes Research Institute	Bipolar I Disorder, Depression	02/30	02/30
NCT05047952: Vortioxetine for Post-COVID-19 Condition	Completed	2	200	Canada	Vortioxetine, Placebo	Brain and Cognition Discovery Foundation	Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment	02/23	02/23
NCT04209296: Chart Review of Patients Undergoing Ketamine Infusions	Completed	N/A	891	Canada	Ketamine Hydrochloride	Brain and Cognition Discovery Foundation	Major Depressive Disorder, Bipolar Disorder, Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder	09/23	09/23
Rosenblat, Joshua D
NCT05029466: Psilocybin for Treatment-Resistant Depression	Completed	2	30	Canada	Psilocybin	Brain and Cognition Discovery Foundation, Braxia Scientific Corp., Usona Institute	Treatment Resistant Depression	07/23	07/23
PSI-1V2, NCT06341426: Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin	Recruiting	2	92	Canada	Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin	University Health Network, Toronto, Centre for Addiction and Mental Health	Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders	02/28	08/28
KET-BD, NCT05004896: Ketamine for Treatment-Resistant Bipolar Disorder	Recruiting	2	100	Canada	Ketamine Hydrochloride, Midazolam Hydrochloride	Joshua Rosenblat	Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder	04/25	12/25
KET-BD-Sustain, NCT05339074: Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression	Recruiting	2	60	Canada	Ketamine Hydrochloride	Joshua Rosenblat	Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder	08/25	02/26
Psilo-BD, NCT06506019: Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression	Recruiting	1	30	Canada	Psilocybin, Functional MRI	University Health Network, Toronto, Centre for Addiction and Mental Health	Bipolar Depression	09/26	01/27
Doyle, Zoe
PSI-1V2, NCT06341426: Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin	Recruiting	2	92	Canada	Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin	University Health Network, Toronto, Centre for Addiction and Mental Health	Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders	02/28	08/28
Psilo-BD, NCT06506019: Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression	Recruiting	1	30	Canada	Psilocybin, Functional MRI	University Health Network, Toronto, Centre for Addiction and Mental Health	Bipolar Depression	09/26	01/27